BACKGROUND: We assessed the morbidity of herpesviruses in patients with type 1 diabetes mellitus (T1D) enrolled in immunosuppressive treatment studies. METHODS:Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus (HSV), and varicella zoster virus (VZV) infections were monitored in 126 participants of a randomized, double-blind, placebo-controlled study of daclizumab (DZB) and mycophenolate mofetil (MMF) including DZB(+)MMF(+), DZB(-)MMF(+), DZB(+)MMF(-), and DZB(-)MMF(-). During the 2-year follow-up, herpesviral infections were monitored clinically, by serology and blood DNA polymerase chain reaction. RESULTS: Among 57 baseline EBV-seronegative participants, 9 developed EBV primary infections, including 2 with infectious mononucleosis syndrome. There were no appreciable differences in the course of the primary EBV infections across treatment groups. Among 69 baseline EBV-seropositive participants, 22 had virologic reactivations, including 1 symptomatic DZB(-)MMF(+) subject. Compared with 7 DZB(-)MMF(-) EBV reactivators, the 9 DZB(+)MMF(+) reactivators tended to have more prolonged viremia (11.4 vs 4.4 months; P = .06) and higher cumulative viral burden (14.2 vs 12.5 log EBV copies/mL; P = .06). Four of 85 baseline CMV-seronegative subjects developed asymptomatic primary CMV infections. There were no CMV reactivations. Of 30 baseline HSV-seropositive subjects, 8 developed ≥1 episode of herpes labialis; 1 subject had a primary HSV infection; and 1 subject without baseline serology information had a new diagnosis of genital HSV. There were no significant differences in the incidence of HSV recurrences across treatment groups. Of 100 baseline VZV-seropositive subjects, 1 DZB(-)MMF(-) subject developed herpes zoster and 1 DZB(-)MMF(+) subject had Bell's palsy possibly related to VZV. CONCLUSIONS: The use of DZB alone or in combination with MMF was not associated with increased morbidity due to herpesviruses. CLINICAL TRIALS REGISTRATION: NCT00100178.
RCT Entities:
BACKGROUND: We assessed the morbidity of herpesviruses in patients with type 1 diabetes mellitus (T1D) enrolled in immunosuppressive treatment studies. METHODS:Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus (HSV), and varicella zoster virus (VZV) infections were monitored in 126 participants of a randomized, double-blind, placebo-controlled study of daclizumab (DZB) and mycophenolate mofetil (MMF) including DZB(+)MMF(+), DZB(-)MMF(+), DZB(+)MMF(-), and DZB(-)MMF(-). During the 2-year follow-up, herpesviral infections were monitored clinically, by serology and blood DNA polymerase chain reaction. RESULTS: Among 57 baseline EBV-seronegative participants, 9 developed EBV primary infections, including 2 with infectious mononucleosis syndrome. There were no appreciable differences in the course of the primary EBV infections across treatment groups. Among 69 baseline EBV-seropositive participants, 22 had virologic reactivations, including 1 symptomatic DZB(-)MMF(+) subject. Compared with 7 DZB(-)MMF(-) EBV reactivators, the 9 DZB(+)MMF(+) reactivators tended to have more prolonged viremia (11.4 vs 4.4 months; P = .06) and higher cumulative viral burden (14.2 vs 12.5 log EBV copies/mL; P = .06). Four of 85 baseline CMV-seronegative subjects developed asymptomatic primary CMV infections. There were no CMV reactivations. Of 30 baseline HSV-seropositive subjects, 8 developed ≥1 episode of herpes labialis; 1 subject had a primary HSV infection; and 1 subject without baseline serology information had a new diagnosis of genital HSV. There were no significant differences in the incidence of HSV recurrences across treatment groups. Of 100 baseline VZV-seropositive subjects, 1 DZB(-)MMF(-) subject developed herpes zoster and 1 DZB(-)MMF(+) subject had Bell's palsy possibly related to VZV. CONCLUSIONS: The use of DZB alone or in combination with MMF was not associated with increased morbidity due to herpesviruses. CLINICAL TRIALS REGISTRATION: NCT00100178.
Authors: Kevan C Herold; William Hagopian; Julie A Auger; Ena Poumian-Ruiz; Lesley Taylor; David Donaldson; Stephen E Gitelman; David M Harlan; Danlin Xu; Robert A Zivin; Jeffrey A Bluestone Journal: N Engl J Med Date: 2002-05-30 Impact factor: 91.245
Authors: L J Swinnen; M R Costanzo-Nordin; S G Fisher; E J O'Sullivan; M R Johnson; A L Heroux; G J Dizikes; R Pifarre; R I Fisher Journal: N Engl J Med Date: 1990-12-20 Impact factor: 91.245
Authors: K A Newell; E M Alonso; P F Whitington; D S Bruce; J M Millis; J B Piper; E S Woodle; S M Kelly; H Koeppen; J Hart; C M Rubin; J R Thistlethwaite Journal: Transplantation Date: 1996-08-15 Impact factor: 4.939
Authors: J K Hamilton; L A Paquin; J L Sullivan; H S Maurer; F G Cruzi; A J Provisor; C P Steuber; E Hawkins; D Yawn; J A Cornet; K Clausen; G Z Finkelstein; B Landing; M Grunnet; D T Purtilo Journal: J Pediatr Date: 1980-04 Impact factor: 4.406
Authors: R C Walker; C V Paya; W F Marshall; J G Strickler; R H Wiesner; J A Velosa; T M Habermann; R C Daly; C G McGregor Journal: J Heart Lung Transplant Date: 1995 Mar-Apr Impact factor: 10.247
Authors: Polly J Bingley; Diane K Wherrett; Ann Shultz; Lisa E Rafkin; Mark A Atkinson; Carla J Greenbaum Journal: Diabetes Care Date: 2018-04 Impact factor: 19.112
Authors: Ronnie Aronson; Peter A Gottlieb; Jens S Christiansen; Thomas W Donner; Emanuele Bosi; Bruce W Bode; Paolo Pozzilli Journal: Diabetes Care Date: 2014-07-10 Impact factor: 19.112
Authors: Rebecca C Wyatt; Giacomo Lanzoni; Mark A Russell; Ivan Gerling; Sarah J Richardson Journal: Curr Diab Rep Date: 2019-12-09 Impact factor: 4.810